Indian drugmaker Sun Pharmaceutical Industries’ (NSE: SUNPHARMA) Ilumya is impressing in a new indication beyond its current plaque psoriasis label, new data presented at EULAR has shown.
The interleukin-23 inhibitor is being studied in a Phase II study in psoriatic arthritis, and an interim analysis has shown that more than 71% of patients treated with Ilumya experienced a 20% improvement in joint and skin symptoms (ACR20), meeting the primary endpoint of the trial.
"We are now exploring a possible Phase III trial for psoriatic arthritis with regulatory authorities"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze